Increased IV-TXA Dosage Reduces Blood Loss, Improves Pain and Clinical Outcomes in TKA Patients
Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial.Arch Orthop Trauma Surg. 2020 Aug;140(8):1087-1095
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Two hundred and two patients with osteoarthrosis or rheumatoid arthritis undergoing a unilateral total knee arthroplasty were randomized to receive either one of the following interventions: 4 doses of Intravenous (IV) Tranexamic acid (TXA), 5 doses of IV-TXA, or 6 doses of IV-TXA or control (no TXA). The primary outcome of interest was hidden blood loss. Additional outcomes measured included the ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE